ArticleJournal of chemical information and modeling2026
Ab-SELDON: Leveraging Diversity Data for an Efficient Automated Computational Pipeline for Antibody Design.
Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The utilization of predictive tools has become increasingly prevalent in the development of biopharmaceuticals, reducing the time and cost of research. However, most methods for computational antibody design are hampered by their reliance on scarcely available antibody structures, potential for immunogenic modifications, and a restricted exploration of the paratope's potential chemical and conformational space. We propose Ab-SELDON, a modular and easily customizable antibody design pipeline capable of iteratively optimizing an antibody-antigen (Ab-Ag) interaction in five different modification steps, including CDR and framework grafting, and mutagenesis. The optimization process is guided by diversity data collected from millions of publicly available human antibody sequences. This approach enhanced the exploration of the chemical and conformational space of the paratope during computational tests involving the optimization of an anti-HER2 antibody. Optimization of another antibody against Gal-3BP stabilized the Ab-Ag interaction in molecular dynamics simulations at lower runtime than alternative pipelines. Tests with SKEMPI's Ab-Ag mutations also demonstrated the pipeline's ability to correctly identify the effect of the majority of mutations, especially multipoint and those that increased binding affinity. This freely available pipeline presents a new approach for computationally efficient and automated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.